MYGN
NASDAQ · Biotechnology
Myriad Genetics Inc
$4.71
+0.10 (+2.17%)
Financial Highlights (FY 2026)
Revenue
875.86M
Net Income
-133,116,705
Gross Margin
69.9%
Profit Margin
-15.2%
Rev Growth
+6.6%
D/E Ratio
0.06
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 69.9% | 69.9% | 31.6% | 31.6% |
| Operating Margin | -14.5% | -13.0% | -16.4% | -19.6% |
| Profit Margin | -15.2% | -14.4% | -21.1% | -16.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 875.86M | 821.32M | 74.53M | 73.26M |
| Gross Profit | 612.14M | 574.02M | 23.57M | 23.17M |
| Operating Income | -126,823,812 | -107,034,349 | -12,223,352 | -14,366,935 |
| Net Income | -133,116,705 | -112,345,306 | -15,758,896 | -11,828,489 |
| Gross Margin | 69.9% | 69.9% | 31.6% | 31.6% |
| Operating Margin | -14.5% | -13.0% | -16.4% | -19.6% |
| Profit Margin | -15.2% | -14.4% | -21.1% | -16.2% |
| Rev Growth | +6.6% | +6.6% | +5.3% | -4.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 10.84M | 10.84M | 122.72M | 106.53M |
| Total Equity | 191.90M | 191.90M | 215.66M | 214.57M |
| D/E Ratio | 0.06 | 0.06 | 0.57 | 0.50 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -63,995,683 | -57,010,407 | -16,042,014 | -17,865,875 |
| Free Cash Flow | — | — | -13,316,178 | -13,196,312 |